←
Cxbladder1,006 posts
Cxbladder avatar

Cxbladder

@Cxbladder

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification, rule-out, and surveillance of urothelial cancer.

◷ Joined July 2010▧ 397 Photos and videos
Cxbladder avatar
Cxbladder@Cxbladder·Nov 5

News to Share! Pacific Edge today announces that the final Local Coverage Determination (LCD) for urine-based biomarkers in patients with microhematuria has been published to the Medicare Coverage Database, confirming Medicare coverage for Cxbladder Triage and Triage Plus. Pacific Edge Chief Executive Dr Peter Meintjes said: “The final LCD is a significant milestone for Pacific Edge, Medicare patients, urologists, and the broader healthcare system. It provides clear guidance on the eligible hematuria patients for which Triage and Triage Plus should be reimbursed and recognizes the important role that validated, non-invasive urine-based biomarkers can play in helping physicians make better-informed decisions about cystoscopy. “The LCD confirms Pacific Edge as the market leader, with only Triage and Triage Plus tests covered under the policy. This leadership is a consequence of its commitment to generating the overwhelming evidence needed to change physician behavior, medical policy, and guidelines.” Learn more: hubs.la/Q04DwPTz0

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Nov 3

Upcoming event! This week the Cxbladder team will be in Chicago alongside independent urology leaders, clinicians and practice administrators at LUGPA 2026. As practices look for new ways to balance high clinical standards with operational efficiency and patient experience, non-invasive genomic urine testing can play an important role, supporting urological teams to refine UC risk stratification in patients presenting with microhematuria. Join us to learn more about Cxbladder Triage Plus, implementation in clinical practice, and how urology teams can focus time and resources where they're needed most.

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 27

New clinical evidence: We’re pleased to confirm that the AUSSIE study has been published in BJU International. AUSSIE – the second peer reviewed clinical validation of Triage Plus and the first in an Australian population – reproduces the performance seen in the recent DRIVE study and gives Australian clinicians and hospitals local peer-reviewed evidence supporting use of the test to help rule out urothelial cancer and defer an invasive cystoscopy and unnecessary imaging in patients with a low probability of disease. For clinical teams outside Australia, AUSSIE provides important new evidence that Cxbladder Triage Plus performs consistently across different patient populations and health systems. Learn more: hubs.la/Q04CqJjC0

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 22

Upcoming event! From Sunday you'll find us in Lahaina, Haiwaii for the 2026 Annual Meeting of the Western Section of the AUA (WSAUA).   Come visit us at the Cxbladder booth to learn how Triage Plus can streamline microhematuria UC risk stratification, allowing clinical teams to focus their resources on those who require care, while helping to defer patients who do not stand to benefit from an invasive cystoscopy.   With the publication of LCD DL40378, Cxbladder Triage Plus is expected to be covered by Medicare for the care of appropriately counseled intermediate risk patients.

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 20

Upcoming event! This week we'll be in Las Vegas for SUNA UroLogic 2026. Join us at the Cxbladder booth #202 to learn how genomic UC risk stratification can help streamline the evaluation of patients presenting with microhematuria.   Empower your team to optimize practice workflow and focus clinical resources on patients who need it the most. Cxbladder Triage Plus combines mRNA and DNA biomarkers to build on the performance of Cxbladder Triage, a test now included in the AUA/SUFU Microhematuria Guideline* with supporting level A evidence.   With the publication of LCD DL 40378, Triage Plus is expected to be covered by Medicare for the care of appropriately counseled intermediate risk patients.   Come and talk to our team at SUNA #UroLogic2026 to learn more!   ==   *  Barocas et al. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490.

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 14

Upcoming APAC event! This Saturday, Oct 17, we'll be in Adelaide for the USANZ South Australia and Northern Territory Section Meeting. Join us to learn how Cxbladder genomic tests are helping clinical teams risk stratify haematuria patients and those being monitored for recurrent NMIBC. #NonInvasive #UCRuleOut

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 8

A thought-provoking conversation with AUA President and Kaiser Permanente Chair of Urology Dr Eugene Rhee on the future of urology and the role of the AUA in advancing innovation, education and collaboration across the specialty. As new diagnostic technologies and precision medicine approaches continue to emerge, evidence-based guidance is critical to informed clinical decision-making and improved patient outcomes. We appreciate the AUA's leadership across urology to help ensure innovation translates to meaningful benefits for patients.

This #UrologyAwarenessMonth, @AmerUrological 2026 President Dr. Eugene Rhee joins #TheUroGist to share how the AUA is helping physicians reconnect with what drew them to urology in the first place: caring for patients. Listen on Spotify: open.spotify.com/episode/1c0…

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Oct 1

Upcoming event! From Sunday, we'll be at the Annual Meeting of the American Urogynecologic Society (AUGS). Tying in to this year's theme - Innovations and Practice-Changing Science, and a meeting focus on forward-thinking research and clinical excellence, we're looking forward to discussing Triage Plus, our next generation Cxbladder genomic test for the risk stratification of patients presenting with microhematuria. To learn more, we invite you to join us at the Cxbladder booth. With the publication of LCD DL40378, Triage Plus is expected to be covered by Medicare in appropriately counseled intermediate risk patients.  #NonInvasive #UCRiskStratification

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Sep 23

Expert Webinar - Cxbladder Triage Plus for Microhematuria Evaluation: hubs.la/Q04y0KJv0 Pacific Edge Chief Medical Officer Dr Tamer Aboushwareb provides an overview, discussing:  - Nuances in hematuria evaluation and the impact of recent AUA/SUFU Microhematuria Guideline changes - The advantages of urine-based genomic testing supported with real world evidence  - The development and clinical validation of Triage Plus, including active studies - Practical considerations in the use of Triage Plus  Watch the video: hubs.la/Q04y0KJv0 US clinicians: With the publication of LCD DL40378, Triage Plus is expected to be covered by Medicare for the evaluation of appropriately counseled intermediate risk microhematuria patients.

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Sep 10

A note for Australian clinical teams: From Monday we'll be exhibiting at the Australian National Rural Health Conference in Adelaide. If you're attending, we invite you to join us and learn more about our suite of Cxbladder non-invasive genomic tests, including Triage Plus, a next generation Cxbladder test for haematuria evaluation, and Cxbladder Monitor for NMIBC surveillance. #UCRiskStratification

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Sep 9

Cxbladder Triage Plus, with added DNA markers, enhances microhematuria risk stratification via significant improvements in NPV, Sensitivity, PPV and Specificity over our established Cxbladder Triage and Detect tests. With the publication of LCD DL40378 in May, we expect that Cxbladder Triage Plus will be covered by Medicare in the United States for the risk stratification of appropriately counselled intermediate risk microhematuria patients. Learn more at hubs.la/Q04x5kt30

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Sep 8

Upcoming event! This week we'll be in Roanoke, Virginia for the Annual Meeting of the Mid-Atlantic Section of the AUA. If you're planning to attend, make sure you stop by and visit us at the Cxbladder booth. We'd love the opportunity to discuss Triage Plus, our next generation Cxbladder test expected to be covered by Medicare for the evaluation of intermediate risk microhematuria patients.  #NonInvasive #UCRiskStratification #MAAUA26

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Aug 26

An update for clinicians around the Asia Pacific region! The Urological Association of Asia (UAA) Congress 2026 begins in Manila on 3 September. If you’re planning to attend, we invite you to join us at Booth #140. Two discussion topics we’ll be leading at the event – the use of Cxbladder Triage Plus for hematuria evaluation and the use of Cxbladder Monitor for NMIBC surveillance. Learn more: hubs.la/Q04vjJDM0 #UAA2026

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Aug 20

Enhanced Microhematuria Risk Stratification - Prioritize Those Who Require Urgent Care. Triage Plus delivers significant improvement in NPV, Sensitivity, PPV and Specificity over our established Cxbladder Triage and Detect tests, empowering clinical teams to optimize practice workflow and focus clinical resources on high risk patients and procedures. Learn more and review the DRIVE study which provides clinical validation: hubs.la/Q04tM8_20. Triage Plus builds on the performance of Cxbladder Triage, a test now included in the AUA/SUFU Microhematuria Guideline. == US Clinicians: With the publication of LCD DL4030378 in May, we expect that Cxbladder Triage Plus will be covered by Medicare for the risk stratification of appropriately consulted intermediate risk microhematuria patients.

Post attachment
Cxbladder avatar
Cxbladder@Cxbladder·Jul 31

An important message for US clinicians: Cxbladder Triage Plus is a next generation Cxbladder test that employs a novel combination of mRNA and DNA biomarkers to enhance microhematuria risk stratification, delivering significant performance improvements over our established Triage and Detect tests. With LCD DL4030378 proposing Medicare coverage for Triage Plus in the risk stratification of appropriately consulted intermediate risk patients, we’re now pleased to offer the test to all our US customers. Learn more: hubs.la/Q04rrxR-0

Post attachment